论文部分内容阅读
血管加压素(抗利尿激素,AVP)参与了机体的多个生理代谢过程。在肾脏,和肽素可以通过与AVP2受体结合发挥抗利尿作用,而在肝脏中,AVP1a受体还参与血小板聚集、血管收缩、糖异生和糖原分解。此外,脑垂体和胰岛的AVP1b受体还参与了调节促肾上腺皮质激素、胰岛素和胰高血糖素分泌。因此,AVP可通过多种机制影响机体生理代谢。和肽素是前血管加压素原C末端的一部分。由于和肽素较AVP更加稳定可靠,敏感性更高,因此常用来作为AVP的替代标志物。既往研究发现,和肽素水平升高与糖尿病、
Vasopressin (vasopressin, AVP) is involved in several physiological processes in the body. In the kidney, copeptin exerts an antidiuretic effect by binding to the AVP2 receptor, whereas in the liver, the AVP1a receptor is also involved in platelet aggregation, vasoconstriction, gluconeogenesis and glycogenolysis. In addition, the pituitary and islet AVP1b receptors are involved in the regulation of adrenocorticotropic hormone, insulin and glucagon secretion. Therefore, AVP can affect the body’s physiological metabolism through a variety of mechanisms. Copeptin is part of the pro-pro-Vasopressin C-terminus. Because copeptin is more stable and reliable than AVP, it is more commonly used as a surrogate marker for AVP. Previous studies have found that copeptin levels and diabetes,